Biologics Development, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA.
Electrophoresis. 2020 Jul;41(13-14):1245-1252. doi: 10.1002/elps.201900435. Epub 2020 May 17.
In the biopharmaceutical industry, CE-SDS assesses the purity, heterogeneity, and stability of therapeutic proteins. However, for mAb-1 and mAb-2, typical CE-SDS under reducing conditions produced atypical protein peak profiles, which led to biased purity results, thus were not acceptable for biologics manufacturing. This bias was caused by the formation of method-induced higher molecular weight artifacts, the levels of which correlated with protein concentration. Here we show that adding sodium tetradecyl and hexadecyl sulfates to the sample and the sieving gel buffer solutions was required to prevent formation of aggregate artifacts and to maintain detergent:protein uniformity, suggesting their importance during the sample preparation steps of heat denaturation and subsequent cooling as well as during capillary migration. For these proteins, we show that this uniformity was likely due to the ability of these detergents to bind proteins with markedly higher affinities compared to SDS. "CE-SC S" methods (where CE-SC S is CGE using detergent composed of a sodium sulfate head group and a hydrocarbon tail, with "C " representing various tail lengths), were developed with a sodium tetradecyl sulfate sample buffer and a sodium hexadecyl sulfate containing sieving gel buffer that minimized artifacts and provided robust characterization and release results for mAb-1 and mAb-2.
在生物制药行业,CE-SDS 用于评估治疗性蛋白质的纯度、异质性和稳定性。然而,对于 mAb-1 和 mAb-2,在还原条件下进行的典型 CE-SDS 会产生非典型的蛋白质峰形,导致纯度结果存在偏差,因此不适用于生物制品的制造。这种偏差是由方法诱导的高分子量人工产物的形成引起的,其水平与蛋白质浓度相关。在这里,我们表明,需要在样品和筛分凝胶缓冲液中添加十四烷基硫酸钠和十六烷基硫酸钠,以防止聚集人工产物的形成并保持去污剂:蛋白质的均匀性,这表明它们在热变性和随后冷却以及在毛细管迁移过程中的样品制备步骤中很重要。对于这些蛋白质,我们表明这种均匀性可能是由于这些去污剂与蛋白质的结合能力明显高于 SDS。开发了“CE-SC S”方法(其中 CE-SC S 是使用由硫酸根头部基团和烃尾部组成的去污剂的 CGE,“C”代表各种尾部长度),该方法使用十四烷基硫酸钠样品缓冲液和含有十六烷基硫酸钠的筛分凝胶缓冲液,最大限度地减少了人工产物的形成,并为 mAb-1 和 mAb-2 提供了可靠的表征和放行结果。